{
  "catalogId": "6aa68918-999f-465f-9a9f-8f4b7a0b761f",
  "name": "IMJUDO",
  "status": "draft",
  "category": "prescription",
  "registrationValidity": "valid",
  "registrationNumber": "174 80 37652 00",
  "treatmentDescriptions": "Hepatocellular CarcinomaIMJUDO in combination with durvalumab is indicated for the first line treatment of adults with advanced or unresectable hepatocellular carcinoma (HCC).Non-Small Cell Lung Cancer (NSCLC)IMJUDO in combination with durvalumab and platinum-based chemotherapy is indicated for the first-line treatment of adults with metastatic NSCLC with no sensitising EGFR mutations or ALK positive mutations.",
  "termsOfIssue": "Prescription required",
  "form": "concentrate for solution for infusion",
  "route": "i.v",
  "site": "",
  "method": "",
  "administrationNotes": "",
  "ingredients": "TREMELIMUMAB/",
  "codes": {
    "atc5": {
      "system": "WHO ATC Classification",
      "code": "L01FX20",
      "name": "TREMELIMUMAB"
    }
  },
  "contraindications": "",
  "sideEffect": "",
  "warnings": "תרופה מוגבלת לרישום ע'י רופא מומחה או הגבלה אחרת",
  "alternativeMedications": [],
  "packaging": [
    {
      "name": "IMJUDO 20MG/ML 1.25 ML 1 VIAL",
      "manufacturer": {
        "name": "אסטראזנקה",
        "countryOfOrigin": "IL"
      },
      "strength": {
        "value": 0,
        "unit": ""
      },
      "quantity": {
        "value": 1.0,
        "unit": "units"
      },
      "packagingDescription": "VIAL GLASS TYPE I",
      "shelfLife": "48",
      "storageConditions": "",
      "codes": {
        "moh": "9475",
        "yarpa": "22336",
        "barcode": "7290013075628"
      },
      "manufacturersAdministrationRecommendation": "",
      "pricing": {
        "currency": "ILS",
        "maxWholesalePrice": 7756.704945,
        "retailMargin": 10.0,
        "maxRetailPrice": 8532.37544,
        "maxPriceWithVAT": 10068.20257
      }
    }
  ],
  "metadata": {
    "version": "1.4",
    "lastUpdated": "2025-08-01T12:18:43.546760"
  }
}